| BackgroundRecent decades' studies have shown that atherosclerosis is a chronic inflammatory disease. This view is being accepted by the majority of medical workers. A lot of basic research and clinical trials confirm that inflammation throughout the atherosclerotic plaque formation, development and instability of the whole process of change. Myeloperoxidase (myeloperoxidase, MPO) and high sensitivity C-reactive protein (high sensitivity C-reactive protein, hs-CRP) are closely related to coronary heart disease and both can be used as predictors of disease risk. However, the joint use of MPO anf hs-CRP for risk stratification in acute coronary syndrome (acute coronary syndrome, ACS) patients has not been reported.ObjectiveBy comparing the concentration of plasma myeloperoxidasa(MPO),high sensitivity C-reactive protein(hs-CRP) in patients with acute coronary syndrome (ACS), stable angina pectoris(SAP) and control subjects, our study,s aim is to explore the relationship between plasma MPO and ACS, to investigate the diagnostic value and usefulness for risk stratification of MPO level connect hs-CRP in ACS.MethodsOur study included one hundred and twenty eight patients that came from the in-patients of the department of cardiovascular medicine. All patients had been completed coronary angiography. According to the result of CAG and the clinic features, they were divided into three groups:ACS group (n=88), SAP group (n=20) and the control group (n=20). Plasma MPO was measured by enzyme-linkeimmunosorbent assay (ELISA) according to the manufacturer instructionsand and serum hs-CRP was detected by immunoturbidimetry. Comparison the difference in plasma MPO and serum hs-CRP among the three groups. Analysis of the relationship between MPO and the ACS. Comparing the difference in the cumulative incidence of sudden cardiac death, non-fatal myocardial infarction, re-myocardial infarction and the necessary revascularization in the the highest quartile of plasma MPO group, serum hs-CRP concentrations in the highest quartile group and the plasma MPO levels and serum concentrations of hs-CRP in the highest quartile group of patients with ACS during hospitalizationResults1. In CG, SAP and ACS groups, the mean level of plasma MPO was 65.27±22.66 U/L,87.33±25.79 U/L,96.68±19.15 U/L respectively, the plasma level of MPO was obviously higher in ACS group than that in SAP and CG groups (P< 0.001). The plasma level of MPO was higher in SAP group than that in CG group (P <0.05)2. In CG, SAP and ACS groups, the mean level of serum hs-CRP was 4.84±5.24 mg/1,5.74±5.31 mg/1,7.83±5.88 mg/1 respectively, the serum hs-CRP was higher in ACS group than that in SAP and CG groups, however, the difference was not significant (P=0.062)3. The Gensini score of coronary artery in SAP and ACS groups was (27.1±22.97), (40.8±31.54) respectively and the difference was not significant (P> 0.05) between them. 4. There was no obvious correlation among the levels of plasma MPO, the serum levels of hs-CRP and the prevalence of risk factors for CHD. Multivariate logistic regression analysis showed that plasma MPO level and white blood cell courts were the significant and independent variables between the patients.5. During hospitalization, the cumulative incidence of major cardiovascular events in plasma MPO and serum hs-CRP in the highest quartile group (MPO≥108.3U/L and hs-CRP≥11.01 mg/L) ACS patients was significantly higher than that in the highest quartile of plasma MPO group (≥108.3U/L) (OR to 0.193,95% CI:0.035-1.057, P=0.045) and serum hs-CRP concentrations in the highest quartile group (≥11.01 mg/L) (OR was 0.092,95% CI:0.017-0.507, P=0.003) in patientsConclusions1 Plasma MPO level in patients with ACS group was significantly higher than SAP group and CG group. Serum hs-CRP concentration in the ACS group was higher than that in SAP group and CG group, but the difference was not statistically meaning. Shows the level of plasma MPO identify unstable plaque sensitive than serum hs-CRP.2 MPO levels in plasma and serum hs-CRP levels than the single indicators can be combined for the risk stratification of patients with ACS to provide a better reference value... |
PDF Full Text Request